00027-0/asset/67ea98c9-fd5f-4c5f-89f8-b0d954e07e18/main.assets/gr2_lrg.jpg)
tirzepatide into muscle and composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial Tirzepatide injection site thigh: guide
Description
Safety is the whole point
Pharmacies making or distributing compounded GLP-1s use active pharmaceutical ingredients (APIs) that often are not evaluated or inspected by the FDA
Your doctor will advise you on when to stop treatment based on your progress and any side effects
Everything below that threshold is based on extrapolation, anecdotal reports, and individual provider experience
